Reven Announces Coronavirus Treatment Acceleration Program (CTAP) Submission to the FDA

Golden, Colorado, Friday, April 3, 2020 3:00pm MDT – Reven, LLC, a biopharmaceutical company that is developing its flagship product Rejuveinix (RJX) for patients with vascular and metabolic related health conditions, announced today that it has submitted a proposal to … Read More

2020/03/28 Reven News Press

A Phase 1, Double-blind, Placebo-controlled, Randomized, Two-Part, Ascending Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Rejuveinix (RJX) in Healthy Participants. Click here for the full study details

2020/03/23 Reven News Press

Reven successfully completes Phase I clinical trials and is pleased to announce completion with no Serious Adverse Events and no Unexpected Adverse Events.  Results are expected to be submitted to the FDA during the next few weeks.

2020/03/22 Reven News Press

Reven announces Phase II Clinical Development plans for upcoming human efficacy trials.  These trials include exploring efficacy as an adjunct therapy for patients suffering Critical Limb Ischemia.  Additional areas of focus in separate trials will be for chronic wound healing … Read More

2020/03/21 Reven News Press

Reven will soon kick off a social media campaign to get the word out about the exciting developments relative to RJX moving through the regulatory pathway. Please seek us out on Facebook, Instagram, Twitter, LinkedIn and like/comment on our posts … Read More

2019/01/22 Reven News Press

Kevin McGovern Joins Reven’s Board of Directors. Reven announces Kevin McGovern as the newest addition to its Board of Directors. Kevin McGovern Press Release

2019/01/17 Reven News Press

Reven Hires Dr. James Carlson. Dr. James Carlson hired as Reven’s Executive Vice President of Development Dr. James Carlson Press Release here: Reven Press Release – 011719  

2019/01/15 Reven News Press

On January 15, 2019 Reven completed their single-ascending-dose (SAD)/ multiple-ascending-dose (MAD) Phase 1 Clinical Trial in the United States. Reven is now in the planning stage of their Phase 2 Clinical Trial that will be conducted in the United States … Read More

2019/01/15 Reven News Press

MAD Cohort 3 completed dosing on January 15, 2019.

2019/01/04 Reven News Press

Reven Hires Susan Moore. Susan Moore hired as Reven’s Senior Director of Regulatory and Clinical Affairs.

2019/01/08 Reven News Press

MAD Cohort 3 begins seven-day dosing period.

2018/12/19 Reven News Press

Reven Hires Natalie Pizzimenti. Natalie Pizzimenti hired as Reven’s Clinical Research Scientist.

2018/12/18 Reven News Press

MAD Cohort 2 completed dosing on December 18, 2018.

2018/12/11 Reven News Press

MAD Cohort 2 begins seven-day dosing period.

2018/12/05 Reven News Press

SAD Cohort 6C doses subjects; SAD Cohort 6 is completed.